Chemotherapeutic Drug Combination Index Description

Slides:

Advertisements

Similar presentations

Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE WI MCF10A HCT HCT116.

Advertisements

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Xenograft TDDoxorubicinCisplatinIfosfamide SGDT/C%EfficacySGDT/C%EfficacySGDT/C%Efficacy OHS > CTPX > SBX6, >

(z=7) (z=7) (z=7) (z=7) MSMS/MS Ba 7702 Bc AH819 Bc Bc AH259 b y y b b 9 2+ b y 33.

Combining functions: Revenue, Cost, and Profit The revenue, cost, and profit for a product, each in terms of dollars for sales of x units, are given below:

CALYPSO Trial: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum- Sensitive Ovarian Cancer Pujade-Lauraine.

MDA-MB h MDA-MB h a MDA-MB h MDA-MB-468 MDA-MB h MDA-MB h MCF-7 48h MCF-7 72h b c ef g h MDA-MB h clomipramine.

Farmer et al Supplementary Figure 1 KU PARP-1 IC 50 = 3.2nM KU PARP-1 IC 50 = 3.4nM KU PARP-1 IC 50 = 730nM a b

Supplementary Figure S1 a

Cost-Sharing for Plans Offered in the Federal Marketplace for 2018

A-I. MD Anderson Cancer Center algorithms for Hodgkin lymphoma

Supplementary Figure 1 Shiota et al.

WEE1 inhibition forces S-phase–arrested cancer cells into mitosis.

الاسبوع الإرشادي.

PGP9.5 ANTIGEN H & E A B Supplementary Figure 1, Ceyhan et al.

A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.

DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs or DNA Hypomethylating Agents in MLL-Rearranged.

Mining our ABCs Cancer Cell

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Artemisinin: Discovery from the Chinese Herbal Garden

Konstantinos C. Siontis et al. JACEP 2016;2:

Physiotherapy management of whiplash-associated disorders (WAD)

Western blots Kleinjan et al., “Drug-tunable multi-dimensional Synthetic Gene Control using Inducible Degron-tagged dCas9 Effectors”. dCas9 dCas9 GFP Histone.

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

FL cells are dependent on BCL6 in a NOTCH2-dependent manner.

Relative risk of major events with atenolol vs placebo

Franklin SS, et al. Circulation 2009;119:243-50

Supplementary Figure S2

Supplemental figure 1B Indicated cell lines were incubated with venetoclax (VEN) in combination with ara-C or idarubicin (IDA), for 48h and viability assessed.

Sequencing at 10,000x using Illumina paired reads

Nat. Rev. Endocrinol. doi: /nrendo

Lutz et al, Neuropsychopharmacology

Supplementary Figure S1

Konstantinos C. Siontis et al. JACEP 2016;2:

Supplementary Figure 2 Shiota et al.

HeLa COS-7 Supplementary Figure S1 Coelho et al (2014) MM pSPL3 MM

Roth et al, Supplementary Figure 1

Supplementary Figure S4

(apoptotic + necrotic)

Nat. Rev. Cardiol. doi: /nrcardio

Network Medicine Strikes a Blow against Breast Cancer

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for.

Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

Study Identification and Selection Process

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

Leto et al., Supplementary Figure S3

Correlation of change in H2 concentration (△H2) haemodynamics or laboratory parameters. Correlation of change in H2 concentration (△H2) haemodynamics or.

Drug sensitivity described by LD50 is similar in cells cultured in 2D or as organoids Drug sensitivity described by LD50 is similar in cells cultured in.

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,

Chloroquine (CQ) improves tumor cell kill when used in combination with vemurafenib and chemotherapy in BRAFV600E-mutant cells. Chloroquine (CQ) improves.

Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol. Cell viability assay in NSCLC cell lines in response to gefitinib and Taxol.

UK paediatric cardiac surgery mortality rate by year for all cases and total number of procedures performed between 2000 and 2009/2010. UK paediatric cardiac.

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

A B Supplementary Figure 1

WNT1 and WNT7B synergistically upregulate canonical Wnt target genes in YCC11 cells. WNT1 and WNT7B synergistically upregulate canonical Wnt target genes.

Table A and B, in vitro synergy of romidepsin and pralatrexate (PDX) in TCL cell lines. Table A and B, in vitro synergy of romidepsin and pralatrexate.

Synergistic effect of CNP and doxorubicin (DOX) on thiol oxidation.

Combination effect of AdTOP-PUMA and chemotherapeutic agents in colon cancer cells. Combination effect of AdTOP-PUMA and chemotherapeutic agents in colon.

Fig. 3. In vivo tumor responses are mechanism of action–specific and concentration-dependent. In vivo tumor responses are mechanism of action–specific.

Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence.

Tipifarnib and bortezomib are synergistic in cytotoxicity assays

Supplementary Figure 1. Combined prevalence of overweight and obesity in female adolescents by area of residency (A) and household living conditions index.

High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput.

--- 6-months’ therapy months’ therapy Supplementary Figure 1.

Determinants of moderate Cardiovascular Health Index Score (achieving three or more risk factor targets), stratified by region conventions as in figure.

Cost-Sharing for Plans Offered in the Federal Marketplace for 2016

Cost-Sharing for Plans Offered in the Federal Marketplace for 2014

Cost-Sharing for Plans Offered in the Federal Marketplace for 2018

Cost-Sharing for Plans Offered in the Federal Marketplace for 2019

Fig. 4 PPM-DD–optimized ND-drug combinations.

Presentation transcript:

Chemotherapeutic Drug Combination Index Description Drug Combination Study Summary (SU-DHL-8) Chemotherapeutic Drug CI (IC90) CI (IC75) CI (IC50) Combination Index Description Bleomycin 0.59 ± 0.04 0.53 ± 0.05 0.48 ± 0.06 Synergy Carboplatin 0.41 ± 0.11 0.47 ± 0.11 0.57 ± 0.11 Chlorambucil 0.73 ± 0.07 0.69 ± 0.07 0.65 ± 0.07 Moderate Synergy Doxorubicin 0.85 ± 0.05 0.76 ± 0.04 0.68 ± 0.04 Etoposide 0.79 ± 0.07 0.76 ± 0.10 0.75 ± 0.14 b Dacetuzumab upregulates Bid (Ramos) Bid 22 kDa C D 0.33 2 4 6 8 24 32 48 56 Hours Supplementary Figure 3 Lewis, et al.